Meningitis Diagnostic Testing Market Size, Share | Report 2022-2030
Meningitis is the inflammation of the spinal and brain cord membrane caused by bacterial or viral infection. Viral infection is most commonly caused by a virus such as enteroviruses, mumps virus, and herpes simplex virus. Bacterial infection is rare but can be fatal if not treated, and is caused by bacteria such as Haemophilus influenzae type b (Hib) bacteria, pneumococcal bacteria, and meningococcal bacteria. According to an article published on 30th September 2021 in BMC, about 1.2 million bacterial meningitis cases are estimated globally every year in Africa.
The infection has emerged to be a global concern due to its long-term consequences and death rates that have the potential to cause an epidemic. The government is providing active support to establish sophisticated meningitis diagnostic test methods and treatment options to eradicate the disease. For instance, National Center for Disease Control provides referral diagnoses for various infectious diseases such as meningitis, malaria, and tuberculosis among others that are not available in medical colleges and hospitals. Thus, government initiatives to support meningitis diagnostic tests are anticipated to boost market growth during the forecast period.
Furthermore, the rising prevalence of HIV/AIDS and infectious diseases are expanding the growth prospects of meningitis diagnostic tests. According to WHO in 2021, about 1.5 million people were diagnosed with HIV and 6,50,000 people died due to HIV & related diseases. In addition, according to CDC in 2019, 7.2 million people visited physicians with parasitic and infectious diseases and 3.4 million people visited the emergency department for the diagnosis of infectious diseases.
Moreover, growing technological advancements and increasing healthcare sector developments are driving market growth. For instance, in July 2022, Abacus Diagnostica launched a CE-marked GenomEra PCR assay kit to aid healthcare professionals in the diagnosis of the four most cost common viruses causing infection, in 70 minutes. This PCR kit avoids the use of unnecessary antibiotics and helps start proper treatment immediately. Similarly, in 2020 BioFire Diagnostics launched the FilmArray ME panel in Taiwan designed to detect 14 pathogens that cause disease frequently and was approved for reimbursement in 2021. Such technological advancements are increasing the accuracy of meningitis diagnostic tests at early stages and are expected to boost market growth.
The market is segmented by test type, end-user, and region. The type segment includes latex agglutination tests, lateral flow assay, PCR assay, ELISA tests, culture test, and others. The end-user segment includes hospitals, diagnostic centers, and others.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Meningitis Diagnostic Testing Market
5.1. COVID-19 Landscape: Meningitis Diagnostic Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Meningitis Diagnostic Testing Market, By Test Type
8.1. Meningitis Diagnostic Testing Market, by Test Type, 2022-2030
8.1.1. Latex Agglutination Tests
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Lateral Flow Assay
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. PCR Assay
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. ELISA Tests
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Culture Test
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Meningitis Diagnostic Testing Market, By End-user
9.1. Meningitis Diagnostic Testing Market, by End-user, 2022-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Diagnostic Centers
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Meningitis Diagnostic Testing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.1.2. Market Revenue and Forecast, by End-user (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.1.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.1.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.2.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.2.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.2.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.2.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.2.6.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.3.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.3.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.3.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.3.6.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.4.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.4.4.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.4.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.4.6.2. Market Revenue and Forecast, by End-user (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.5.2. Market Revenue and Forecast, by End-user (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.5.3.2. Market Revenue and Forecast, by End-user (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
10.5.4.2. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 11. Company Profiles
11.1. Thermo Fisher Scientific, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bio-Rad Laboratories, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbott Laboratories
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. ELITechGroup
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. BioFire Diagnostics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Fast Track Diagnostics Ltd. (FTD) – Siemens Healthineers
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Seegene, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Luminex Corporation
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Qnostics Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. IMMY
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers